<DOC>
	<DOCNO>NCT00211224</DOCNO>
	<brief_summary>NNIPPS clinical trial riluzole ( drug previously show slow rate progression og amyotrophic lateral sclerosis-ALS ; Lou Gehrig 's disease ) involve nearly 800 people diagnose 'parkinson plus ' syndrome multiple system atrophy ( MSA ) progressive supranuclear plasy ( PSP ) . In addition show whether riluzole helpful MSA PSP , NNIPPS improve criterion make accurate early diagnosis , assess rate progression , advance understanding biology disable progressive neurodegenerative disease .</brief_summary>
	<brief_title>Neuroprotection Natural History Parkinson 's Plus Syndromes ( NNIPPS )</brief_title>
	<detailed_description>Multiple System Atrophy ( MSA ) Progressive Supranuclear Palsy ( PSP ) often present akinetic-rigid syndrome early stage difficult differentiate clinic . Current Consensus Diagnostic Criteria base retrospective study high specificity low sensitivity . The NNIPPS study EU-funded multinational ( France , UK , Germany ) multi-centre academic-led project four main aim . The first aim test hypothesis riluzole , may generic neuroprotective property , reduces risk death improves function quality life ( QL ) patient MSA PSP- ‘ parkinson ’ plus syndrome ’ . The second aim identify prognostic factor survival functional deterioration , develop validate functional rating scale prospectively . The third aim investigate MRI , cognitive , pathological genetic aspect disorder relation disease progression pathogenesis . The fourth aim understand impact disease QL patient carers identify health cost treatment . The study design randomise , stratify , control trial efficacy safety riluzole ( 200mg daily ) versus placebo MSA PSP . The primary outcome measure survival 36 month . Power calculation suggest would need recruit ~400 patient stratum ( MSA , PSP ) order detect reduction relative risk ( RR ) death 36 month 80 % power two-sided a=0.05 . Using modified consensus criterion ( provide great sensitivity ) recruit 766 patient ( 363 PSP , 404 MSA ) 2 year ( 1999-2001 ) . The first patient recruit enter open-label study . The final analysis primary efficacy measure plan December 2005 . Secondary outcome measure include safety , rate change UPDRS rating scale include parkinson ’ plus symtoms rating scale ( PPSS ) , change cognitive function assess use Mattis Dementia Rating Scale , Frontal Assessment Battery , The Bushke Selective Reminding Test , The Neuropsychiatric Inventory , test memory executive function . QL Health economic data collect use SF36 Client Service Receipt Inventory ( CSRI ) . Assessments make 6 monthly interval . Standardised MRI acquire ~70 % case entry repeat 36 month possible . DNA collect ~75 % case . 100 brain donate analysed use standardise protocol .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>akinetic rigid syndrome plus clinical criterion MSA PSP Idiopathic Parkinson 's disease Other neurological serious medical disorder Unable give inform consent dementia liver damage woman child bear age unable use effective method contraception</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>multiple system atrophy</keyword>
	<keyword>progressive supranuclear palsy</keyword>
	<keyword>riluzole</keyword>
	<keyword>MSA</keyword>
	<keyword>PSP</keyword>
</DOC>